Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 24;46(12):13443-13455.
doi: 10.3390/cimb46120802.

Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases

Vesna Ćeriman Krstić  1   2 , Natalija Samardžić  2 , Milija Gajić  2 , Milan Savić  1   3 , Biljana Šeha  4 , Marina Roksandić Milenković  5 , Dragana Jovanović  6
Affiliations
Review

Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases

Vesna Ćeriman Krstić et al. Curr Issues Mol Biol. .

Abstract

Lung cancer represents the most common cause of cancer-related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases have worse prognosis, with an overall survival (OS) from three to six months. The majority of them have a poor response to chemotherapy, and the data are controversial regarding the response to immunotherapy. This could be because the liver is considered to be an immune-tolerant organ, which is characterized by T-cell anergy and immunosuppressive signals. This review evaluates current treatment options for patients with NSCLC and liver metastases. Combination therapies might be a better treatment option for this subgroup of patients. The addition of radiotherapy to immunotherapy could also be an option in selected patients. The resection of single liver metastasis should also be considered.

Keywords: NSCLC; combination therapies; immunotherapy; liver metastases; radiotherapy; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Global Data Non-Small Cell Lung Cancer (NSCLC)—Epidemiology Forecast to 2025. [(accessed on 15 May 2021)]. Available online: https://store.globaldata.com/report/gdhcer132-16--epicast-report-non-sma...
    1. Qin B.D., Jiao X.D., Liu J., Liu K., He X., Wu Y., Ling Y., Duan X.P., Qin W.X., Wang Z., et al. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Crit. Rev. Oncol. Hematol. 2020;147:102893. doi: 10.1016/j.critrevonc.2020.102893. - DOI - PubMed
    1. Riihimäki M., Hemminki A., Fallah M., Thomsen H., Sundquist K., Sundquist J., Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78–84. doi: 10.1016/j.lungcan.2014.07.020. - DOI - PubMed
    1. Qu F.J., Zhou Y., Wu S. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases. Br. J. Cancer. 2024;130:165–175. doi: 10.1038/s41416-023-02482-w. - DOI - PMC - PubMed
    1. Tamura T., Kurishima K., Nakazawa K., Kagohashi K., Ishikawa H., Satoh H., Hizawa N. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol. Clin. Oncol. 2015;3:217–221. doi: 10.3892/mco.2014.410. - DOI - PMC - PubMed

LinkOut - more resources